Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression

Nanae Tanemura, Yoshiaki Uyama, Kengo Nagashima, Takahiro Suzuki, Yasuko Asahina, Yoshio Kobayashi, Masaomi Iyo, Koutaro Yokote, Hideki Hanaoka

Research output: Contribution to journalArticle

Abstract

Background: In this study, differences in older patients between drug use as reported in clinical practice and in clinical trials for regulatory approval were examined. Methods: Electronic medical record (EMR) data such as patient background (age, sex), concomitant drugs, data on laboratory tests, and prescribed doses of drugs from outpatients with rheumatoid arthritis, diabetes, high blood pressure, or depression at Chiba University Hospital were obtained for the period from January 2003 to December 2012. These data were compared with data from relevant clinical trials for regulatory approval in order to examine differences in drug use. Results: There were 5134 eligible patients. The prescribed doses of drugs were lower than the standard approved doses for depression and rheumatoid arthritis but were generally within the approved dose range for type 2 diabetes mellitus and hypertension. When comparing the characteristics of older patients taking tacrolimus, 5.6% to 17.0% of those would not be able to participate in clinical trials because of liver or renal abnormality, and the incidence rates of some adverse drug events (ADEs) differed significantly between clinical practice and clinical trials. Conclusions: Appropriate doses of drugs for older patients may differ from approved doses in certain diseases. Complex situations such as a lot of polypharmacy, comorbidity, and functional impairment in older patients in clinical practice make it difficult to evaluate safety based on data from clinical trials. In the future, utilization of a database created from the EMR of older patients should be considered for assessment of drug safety in older patients in clinical practice.

Original languageEnglish
Pages (from-to)743-750
Number of pages8
JournalTherapeutic Innovation and Regulatory Science
Volume50
Issue number6
DOIs
Publication statusPublished - 2016 Nov 1
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Hypertension
Pharmaceutical Preparations
Clinical Trials
Electronic Health Records
Safety
Polypharmacy
Tacrolimus
Drug-Related Side Effects and Adverse Reactions
Type 2 Diabetes Mellitus
Comorbidity
Outpatients
Databases
Kidney
Liver
Incidence

Keywords

  • aged society
  • appropriate doses
  • approved dose
  • drug development
  • drug safety
  • geriatric

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

Comparison of Drug Use Between Clinical Practice and Regulatory Approval : Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression. / Tanemura, Nanae; Uyama, Yoshiaki; Nagashima, Kengo; Suzuki, Takahiro; Asahina, Yasuko; Kobayashi, Yoshio; Iyo, Masaomi; Yokote, Koutaro; Hanaoka, Hideki.

In: Therapeutic Innovation and Regulatory Science, Vol. 50, No. 6, 01.11.2016, p. 743-750.

Research output: Contribution to journalArticle

Tanemura, Nanae ; Uyama, Yoshiaki ; Nagashima, Kengo ; Suzuki, Takahiro ; Asahina, Yasuko ; Kobayashi, Yoshio ; Iyo, Masaomi ; Yokote, Koutaro ; Hanaoka, Hideki. / Comparison of Drug Use Between Clinical Practice and Regulatory Approval : Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression. In: Therapeutic Innovation and Regulatory Science. 2016 ; Vol. 50, No. 6. pp. 743-750.
@article{2708b29c2b0e48db9b9df1ed4b9f79c7,
title = "Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression",
abstract = "Background: In this study, differences in older patients between drug use as reported in clinical practice and in clinical trials for regulatory approval were examined. Methods: Electronic medical record (EMR) data such as patient background (age, sex), concomitant drugs, data on laboratory tests, and prescribed doses of drugs from outpatients with rheumatoid arthritis, diabetes, high blood pressure, or depression at Chiba University Hospital were obtained for the period from January 2003 to December 2012. These data were compared with data from relevant clinical trials for regulatory approval in order to examine differences in drug use. Results: There were 5134 eligible patients. The prescribed doses of drugs were lower than the standard approved doses for depression and rheumatoid arthritis but were generally within the approved dose range for type 2 diabetes mellitus and hypertension. When comparing the characteristics of older patients taking tacrolimus, 5.6{\%} to 17.0{\%} of those would not be able to participate in clinical trials because of liver or renal abnormality, and the incidence rates of some adverse drug events (ADEs) differed significantly between clinical practice and clinical trials. Conclusions: Appropriate doses of drugs for older patients may differ from approved doses in certain diseases. Complex situations such as a lot of polypharmacy, comorbidity, and functional impairment in older patients in clinical practice make it difficult to evaluate safety based on data from clinical trials. In the future, utilization of a database created from the EMR of older patients should be considered for assessment of drug safety in older patients in clinical practice.",
keywords = "aged society, appropriate doses, approved dose, drug development, drug safety, geriatric",
author = "Nanae Tanemura and Yoshiaki Uyama and Kengo Nagashima and Takahiro Suzuki and Yasuko Asahina and Yoshio Kobayashi and Masaomi Iyo and Koutaro Yokote and Hideki Hanaoka",
year = "2016",
month = "11",
day = "1",
doi = "10.1177/2168479016648731",
language = "English",
volume = "50",
pages = "743--750",
journal = "Therapeutic Innovation and Regulatory Science",
issn = "2168-4790",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of Drug Use Between Clinical Practice and Regulatory Approval

T2 - Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression

AU - Tanemura, Nanae

AU - Uyama, Yoshiaki

AU - Nagashima, Kengo

AU - Suzuki, Takahiro

AU - Asahina, Yasuko

AU - Kobayashi, Yoshio

AU - Iyo, Masaomi

AU - Yokote, Koutaro

AU - Hanaoka, Hideki

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: In this study, differences in older patients between drug use as reported in clinical practice and in clinical trials for regulatory approval were examined. Methods: Electronic medical record (EMR) data such as patient background (age, sex), concomitant drugs, data on laboratory tests, and prescribed doses of drugs from outpatients with rheumatoid arthritis, diabetes, high blood pressure, or depression at Chiba University Hospital were obtained for the period from January 2003 to December 2012. These data were compared with data from relevant clinical trials for regulatory approval in order to examine differences in drug use. Results: There were 5134 eligible patients. The prescribed doses of drugs were lower than the standard approved doses for depression and rheumatoid arthritis but were generally within the approved dose range for type 2 diabetes mellitus and hypertension. When comparing the characteristics of older patients taking tacrolimus, 5.6% to 17.0% of those would not be able to participate in clinical trials because of liver or renal abnormality, and the incidence rates of some adverse drug events (ADEs) differed significantly between clinical practice and clinical trials. Conclusions: Appropriate doses of drugs for older patients may differ from approved doses in certain diseases. Complex situations such as a lot of polypharmacy, comorbidity, and functional impairment in older patients in clinical practice make it difficult to evaluate safety based on data from clinical trials. In the future, utilization of a database created from the EMR of older patients should be considered for assessment of drug safety in older patients in clinical practice.

AB - Background: In this study, differences in older patients between drug use as reported in clinical practice and in clinical trials for regulatory approval were examined. Methods: Electronic medical record (EMR) data such as patient background (age, sex), concomitant drugs, data on laboratory tests, and prescribed doses of drugs from outpatients with rheumatoid arthritis, diabetes, high blood pressure, or depression at Chiba University Hospital were obtained for the period from January 2003 to December 2012. These data were compared with data from relevant clinical trials for regulatory approval in order to examine differences in drug use. Results: There were 5134 eligible patients. The prescribed doses of drugs were lower than the standard approved doses for depression and rheumatoid arthritis but were generally within the approved dose range for type 2 diabetes mellitus and hypertension. When comparing the characteristics of older patients taking tacrolimus, 5.6% to 17.0% of those would not be able to participate in clinical trials because of liver or renal abnormality, and the incidence rates of some adverse drug events (ADEs) differed significantly between clinical practice and clinical trials. Conclusions: Appropriate doses of drugs for older patients may differ from approved doses in certain diseases. Complex situations such as a lot of polypharmacy, comorbidity, and functional impairment in older patients in clinical practice make it difficult to evaluate safety based on data from clinical trials. In the future, utilization of a database created from the EMR of older patients should be considered for assessment of drug safety in older patients in clinical practice.

KW - aged society

KW - appropriate doses

KW - approved dose

KW - drug development

KW - drug safety

KW - geriatric

UR - http://www.scopus.com/inward/record.url?scp=84992469972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992469972&partnerID=8YFLogxK

U2 - 10.1177/2168479016648731

DO - 10.1177/2168479016648731

M3 - Article

AN - SCOPUS:84992469972

VL - 50

SP - 743

EP - 750

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

SN - 2168-4790

IS - 6

ER -